Q Chip and ARTES Biotechnology announce collaboration to develop sustained release formulations of therapeutic proteins
Q Chip Ltd and ARTES Biotechnology GmbH announced that they have signed a Collaborative Agreement to explore the development of a new sustained release formulations of interferon alpha 2a for the treatment of chronic hepatitis B and C.
The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with the current marketed pegylated therapies which require weekly administration. Q Chip will be developing a one month sustained release microsphere formulation This first phase of the collaboration is expected to be completed by the end of 2010.
The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere composed of biocompatible polymers. The microsphere will be loaded with interferon alpha 2a manufactured from ARTES´ proprietary yeast Hansenula polymorpha expression system. ARTES will supply interferon alpha 2a and Q Chip will formulate the Q-Sphera microspheres.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.